The Boston Lung Cancer Survival Cohort

波士顿肺癌生存队列

• 批准号: 10415930
• 负责人: David C Christiani
• 金额: $ 125.35万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10415930
• 关键词: Archives; Area; Award; Basic Science; Biological; Biological Markers; Boston; Cancer Center; Cancer Patient; Cessation of life; Chronic Obstructive Pulmonary Disease; Clinical; Clinical Cancer Center; Clinical Research; Cohort Studies; Collaborations; Computerized Medical Record; Coupling; DNA; DNA Methylation; Dana-Farber Cancer Institute; Data; Data Management Resources; Databases; Development; Diet; Dimensions; Disease; Enrollment; Environment; Epidemiologic Methods; Epidemiology; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Erlotinib; Evaluation; Factor Analysis; Follow-Up Studies; Future; Gefitinib; General Hospitals; Genetic; Genomics; Grant; Heterogeneity; High Resolution Computed Tomography; Histology; Immunotherapy; Infrastructure; Interdisciplinary Study; International; Laboratories; Leukocytes; Link; Lung; Lung Adenocarcinoma; Malignant Neoplasms; Malignant neoplasm of lung; Massachusetts; Methodology; Methods; Methylation; Molecular; Mutation; Natural History; Occupational; Oncogenic; Outcome; Participant; Patients; Pharmaceutical Preparations; Phenotype; Physical activity; Pilot Projects; Population Heterogeneity; Quality Control; Questionnaires; Recurrence; Research; Research Design; Research Methodology; Research Personnel; Resource Sharing; Resources; Risk Factors; Sampling; Secure; Serum; Smoking; Smoking History; Structure of parenchyma of lung; Survivors; System; Therapeutic; Tissues; Toxic effect; Translational Research; Treatment Efficacy; Treatment outcome; Treatment-related toxicity; Tumor Tissue; U-Series Cooperative Agreements; United States; Update; Urine; Weight; X-Ray Computed Tomography; automated image analysis; biobank; bioinformatics pipeline; cancer epidemiology; cancer survival; cell free DNA; clinical investigation; cohort; data management; data quality; data sharing; dietary; driver mutation; epidemiologic data; follow-up; genetic epidemiology; genome-wide; genotyped patients; indexing; innovation; lung imaging; lung small cell carcinoma; member; method development; microbiome research; mortality; multidisciplinary; mutational status; new technology; next generation sequencing; novel; pathology imaging; predictive marker; prognostic; programs; prospective; pulmonary function; radiomics; recruit; respiratory; response; screening program; survival outcome; survival prediction; targeted treatment; traditional therapy; transcriptomics; translational medicine; treatment response; tumor

ABSTRACT Lung cancer is a heterogeneous disease and the leading cancer-related killer in the United States. Understanding the molecular causes of this heterogeneity is the focus of current basic and translational research. The Boston Lung Cancer Study (BLCS) is cancer epidemiology cohort of over 11,000 lung cancer cases enrolled at Massachusetts General Hospital and the Dana-Farber Cancer Institute from 1992-present. This is the first and most comprehensive survivor cohort with the longest follow-up period, and will grow to over 14,000 by the end of this proposed cycle with additional recruitment to enhance the samples with oncogenic driver mutation status. By identifying the relevant patients and providing critical archived tumor tissues, through collaboration within the Dana- Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Program, the BLCS supported the first discovery of the association between EGFR mutations and response to therapy with EGFR-TKIs, initiating the era of targeted therapy in lung cancer. We are now applying for support of the existing cohort infrastructure and resume the recruitment of new cases through a cooperative agreement. The overarching aims are 3-fold: 1) To maintain the lung cancer core cohort and maximize its potential for future scientific needs for lung cancer survival research; 2) To enable cutting- edge research questions by epidemiologic methods development methodologic, and piloting approaches that will turn into productive multidisciplinary project grants aimed at studying various aspects of survival, as well as treatment toxicity; and 3) To leverage the DF/HCC lung program resources for creative multidisciplinary collaborations focused on treatment outcomes. The rationale for recruiting new cases into the large cohort include: 1) facilitating the evaluation between new treatments and traditional therapy and the study design of new clinical investigation in an ever-changing therapeutic environment; 2) collecting more cases with rare oncogenic driver mutations; 3) including patients with accurate histology, smoking histories, and mutational load analyses treated with immunotherapy; 4) collecting repeated biological samples suitable for development of prognostic/predictive biomarkers; and 5) allowing better assessment of the less-studied small-cell lung cancer (SCLC). This application will also support us to establish an innovative COPD phenotyping database via automated image analysis of high- resolution computed tomography, as well as a radiomics data base, as well as to develop a new method of analyzing linked genetic epidemiologic data and information from electronic medical records (EMR) with support from an ongoing R35 award (Dr. Xihong Lin). The BLCS cohort is one of the few survival cohorts contributing substantial data on survival status, with tumor mutation data and tissue available. The combination of biomarker data, tumor molecular characterization, CT imaging and traditional epidemiologic risk factor data will allow powerful translational research and provide unique opportunities to further explore predictors of survival and treatment outcomes. We aim to maintain the quality of the BLCS follow-up and associated data as well as to develop approaches that will provide novel opportunities to investigators.

摘要